GE HealthCare Technologies Inc. logo

GE HealthCare Technologies Inc. (GEHC)

Market Closed
24 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
76. 77
-0.48
-0.62%
$
33.96B Market Cap
28.36 P/E Ratio
0.12% Div Yield
2,345,780 Volume
4.3 Eps
$ 77.25
Previous Close
Day Range
76.32 77.86
Year Range
57.65 94.8
Want to track GEHC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 5 days

Summary

GEHC closed today lower at $76.77, a decrease of 0.62% from yesterday's close, completing a monthly increase of or $76.77. Over the past 12 months, GEHC stock gained .
GEHC pays dividends to its shareholders, with the most recent payment made on May 15, 2025. The next announced payment will be in In 3 weeks on Aug 15, 2025 for a total of $0.035.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.09%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

GEHC Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
GE HealthCare Stock: Hidden Winner Of Alzheimer's Drug Boom

GE HealthCare Stock: Hidden Winner Of Alzheimer's Drug Boom

GE HealthCare Technologies is one of the leaders in the healthcare sector, with a strong position in the global molecular imaging market. GE HealthCare's Pharmaceutical Diagnostics segment's EBIT was $205 million in Q1 2025, up 15.2% year over year. I expect it to rise to $245 million in Q2, driven by increased sales of Vizamyl, which is used to prescribe anti-amyloid drugs for the treatment of Alzheimer's disease.

Seekingalpha | 3 days ago
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications

GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications

GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.

Zacks | 4 weeks ago
GE Healthcare: Near-Term Margin Headwinds Priced In, Long-Term Growth Driven By New Products And M&As

GE Healthcare: Near-Term Margin Headwinds Priced In, Long-Term Growth Driven By New Products And M&As

GE Healthcare is well-positioned for growth, driven by a strong backlog, product innovation, and potential pent-up demand in China as stimulus funding is deployed. Margin headwinds from tariffs are expected to bottom in Q3, with management actively mitigating impacts through cost controls, local manufacturing, and pricing actions. Valuation is attractive versus peers, with current prices reflecting tariff risks and offering upside as margins recover and growth accelerates post-Q3.

Seekingalpha | 1 month ago

GE HealthCare Technologies Inc. Dividends

GE HealthCare Technologies Inc. logo
GEHC Today
Announced
Quarterly
$0.04 Per Share
GE HealthCare Technologies Inc. logo
GEHC 3 months ago
Paid
Quarterly
$0.04 Per Share
GE HealthCare Technologies Inc. logo
GEHC 6 months ago
Paid
Quarterly
$0.04 Per Share
GE HealthCare Technologies Inc. logo
GEHC 9 months ago
Paid
Quarterly
$0.03 Per Share
GE HealthCare Technologies Inc. logo
GEHC 19 Jul 2024
Paid
Quarterly
$0.03 Per Share

GE HealthCare Technologies Inc. Earnings

30 Jul 2025 (In 5 days) Date
0.91
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
13 Feb 2025 Date
1.26
Cons. EPS
1.45
EPS
30 Oct 2024 Date
1.05
Cons. EPS
1.14
EPS
31 Jul 2024 Date
0.98
Cons. EPS
1
EPS
GE HealthCare Technologies Inc. logo
GEHC Today
Announced
Quarterly
$0.04 Per Share
GE HealthCare Technologies Inc. logo
GEHC 3 months ago
Paid
Quarterly
$0.04 Per Share
GE HealthCare Technologies Inc. logo
GEHC 6 months ago
Paid
Quarterly
$0.04 Per Share
GE HealthCare Technologies Inc. logo
GEHC 9 months ago
Paid
Quarterly
$0.03 Per Share
GE HealthCare Technologies Inc. logo
GEHC 19 Jul 2024
Paid
Quarterly
$0.03 Per Share
30 Jul 2025 (In 5 days) Date
0.91
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
13 Feb 2025 Date
1.26
Cons. EPS
1.45
EPS
30 Oct 2024 Date
1.05
Cons. EPS
1.14
EPS
31 Jul 2024 Date
0.98
Cons. EPS
1
EPS

GE HealthCare Technologies Inc. (GEHC) FAQ

What is the stock price today?

The current price is $76.77.

On which exchange is it traded?

GE HealthCare Technologies Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is GEHC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.12%.

What is its market cap?

As of today, the market cap is 33.96B.

What is the earnings per share?

The EPS is 0.91.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has GE HealthCare Technologies Inc. ever had a stock split?

No, there has never been a stock split.

GE HealthCare Technologies Inc. Profile

Medical - Healthcare Information Services Industry
Healthcare Sector
Peter J. Arduini CEO
NASDAQ (NGS) Exchange
36266G107 Cusip
US Country
53,000 Employees
25 Jul 2025 Last Dividend
- Last Split
4 Jan 2023 IPO Date

Overview

GE HealthCare Technologies Inc. is a globally recognized company deeply engaged in the healthcare sector, providing a wide range of products, services, and digital solutions aimed at improving patient care. With operations spread across the United States, Canada, and other international markets, the company commits itself to the development, manufacture, and marketing of innovative medical technologies. The organizational structure of GE HealthCare Technologies Inc. is divided into four primary segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, each dedicated to addressing specific medical needs and advancing the field of medical diagnostics and patient care. Having evolved from GE Healthcare Holding LLC in December 2022, the company is now based in Chicago, Illinois, and continues to leverage its broad portfolio to facilitate the diagnosis, treatment, and monitoring of patients worldwide.

Products and Services

  • Imaging

    This segment provides a comprehensive range of imaging technologies such as molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. These advanced imaging solutions play a crucial role in diagnosing and managing various health conditions, enhancing the efficiency and effectiveness of medical treatments.

  • Ultrasound

    GE HealthCare Technologies Inc. offers a wide array of ultrasound devices and solutions designed for screening, diagnosis, treatment, and monitoring of diseases in numerous clinical areas. This includes radiology, primary care, women's health, cardiovascular, along with point of care and handheld ultrasound devices, and products for surgical visualization and guidance. Ultrasound technology facilitates non-invasive diagnostics and therapeutic procedures, making it an essential tool in modern healthcare.

  • Patient Care Solutions

    The company's offerings under this segment encompass a variety of medical devices, consumables, services, and digital solutions aimed at improving patient outcomes. The portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, and maternal infant care products, alongside a range of consumables and services. These solutions are integral to providing comprehensive care in various medical settings, from emergency rooms to intensive care units and beyond.

  • Pharmaceutical Diagnostics

    Specializing in diagnostic agents for radiology and nuclear medicine, this segment supplies essential products for CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound imaging. The products include contrast media pharmaceuticals that improve the visibility of tissues during diagnostic scans and molecular imaging agents or radiopharmaceuticals labeled with radioisotopes for detailed imaging studies. These diagnostic agents are pivotal in detecting and monitoring a wide range of diseases, aiding clinicians in formulating effective treatment plans.

Contact Information

Address: 500 West Monroe Street
Phone: 617 443 3400